These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 18338812)

  • 21. Activation of the platelet-derived growth factor-receptor enhances survival of murine bone endothelial cells.
    Langley RR; Fan D; Tsan RZ; Rebhun R; He J; Kim SJ; Fidler IJ
    Cancer Res; 2004 Jun; 64(11):3727-30. PubMed ID: 15172974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors.
    Hofer MD; Fecko A; Shen R; Setlur SR; Pienta KG; Tomlins SA; Chinnaiyan AM; Rubin MA
    Neoplasia; 2004; 6(5):503-12. PubMed ID: 15548358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dependence of autocrine growth factor stimulation in platelet-derived growth factor-B-induced mouse brain tumor cells.
    Uhrbom L; Hesselager G; Ostman A; Nistér M; Westermark B
    Int J Cancer; 2000 Feb; 85(3):398-406. PubMed ID: 10652433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes.
    Ruan J; Luo M; Wang C; Fan L; Yang SN; Cardenas M; Geng H; Leonard JP; Melnick A; Cerchietti L; Hajjar KA
    Blood; 2013 Jun; 121(26):5192-202. PubMed ID: 23632889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.
    Lev DC; Kim SJ; Onn A; Stone V; Nam DH; Yazici S; Fidler IJ; Price JE
    Clin Cancer Res; 2005 Jan; 11(1):306-14. PubMed ID: 15671560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.
    Kinsella P; Howley R; Doolan P; Clarke C; Madden SF; Clynes M; Farrell M; Amberger-Murphy V
    Exp Cell Res; 2012 Mar; 318(5):641-52. PubMed ID: 22285130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Rα/ß expression in squamous cell carcinoma of the head and neck in vitro.
    Schultz JD; Rotunno S; Riedel F; Anders C; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
    Int J Oncol; 2011 Apr; 38(4):1001-12. PubMed ID: 21249316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of Kit and platelet-derived growth factor receptors alpha and beta in cholangiocarcinoma, and case report of therapy with imatinib mesylate (STI571).
    Holcombe RF; Gu M; Imagawa D; Milovanovic T
    Anticancer Drugs; 2003 Sep; 14(8):651-7. PubMed ID: 14501388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of platelet-derived growth factor (PDGF)-B and PDGF-receptor β is associated with lymphatic metastasis in human gastric carcinoma.
    Kodama M; Kitadai Y; Sumida T; Ohnishi M; Ohara E; Tanaka M; Shinagawa K; Tanaka S; Yasui W; Chayama K
    Cancer Sci; 2010 Sep; 101(9):1984-9. PubMed ID: 20624165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB.
    Aoki M; Nabeshima K; Koga K; Hamasaki M; Suzumiya J; Tamura K; Iwasaki H
    Lab Invest; 2007 Aug; 87(8):767-79. PubMed ID: 17558420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. C-kit expression in human osteosarcoma and in vitro assays.
    Miiji LN; Petrilli AS; Di Cesare S; Odashiro AN; Burnier MN; de Toledo SR; Garcia RJ; Alves MT
    Int J Clin Exp Pathol; 2011; 4(8):775-81. PubMed ID: 22135725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential effects of imatinib on PDGF-induced proliferation and PDGF receptor signaling in human arterial and venous smooth muscle cells.
    Li L; Blumenthal DK; Masaki T; Terry CM; Cheung AK
    J Cell Biochem; 2006 Dec; 99(6):1553-63. PubMed ID: 16817200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
    Wen PY; Yung WK; Lamborn KR; Norden AD; Cloughesy TF; Abrey LE; Fine HA; Chang SM; Robins HI; Fink K; Deangelis LM; Mehta M; Di Tomaso E; Drappatz J; Kesari S; Ligon KL; Aldape K; Jain RK; Stiles CD; Egorin MJ; Prados MD
    Neuro Oncol; 2009 Dec; 11(6):853-60. PubMed ID: 19293394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effect of imatinib mesylate on bleomycin-induced pulmonary fibrosis in mice].
    Li L; Li YQ
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2007 Apr; 19(4):229-32. PubMed ID: 17448279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PDGF BB induces VEGF secretion in ovarian cancer.
    Matei D; Kelich S; Cao L; Menning N; Emerson RE; Rao J; Jeng MH; Sledge GW
    Cancer Biol Ther; 2007 Dec; 6(12):1951-9. PubMed ID: 18075302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis.
    Horak P; Wöhrer A; Hassler M; Hainfellner J; Preusser M; Marosi C
    J Neurooncol; 2012 Sep; 109(2):323-30. PubMed ID: 22610940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imatinib mesylate inhibits cell growth of malignant peripheral nerve sheath tumors in vitro and in vivo through suppression of PDGFR-β.
    Ohishi J; Aoki M; Nabeshima K; Suzumiya J; Takeuchi T; Ogose A; Hakozaki M; Yamashita Y; Iwasaki H
    BMC Cancer; 2013 May; 13():224. PubMed ID: 23642185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Growth inhibition of rat osteosarcoma and malignant fibrous histiocytoma cells by tyrosine kinase inhibitor STI571.
    Yoshitani K; Honoki K; Morishita T; Kido A; Miyauchi Y; Mii Y; Takakura Y
    In Vivo; 2003; 17(3):255-8. PubMed ID: 12929576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential roles of growth factor PDGF-BB in the bony repair of injured growth plate.
    Chung R; Foster BK; Zannettino AC; Xian CJ
    Bone; 2009 May; 44(5):878-85. PubMed ID: 19442606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation.
    Matei D; Chang DD; Jeng MH
    Clin Cancer Res; 2004 Jan; 10(2):681-90. PubMed ID: 14760091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.